{"database": "openregs", "table": "federal_register", "rows": [["2012-3552", "Draft Guidance for Industry on Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Availability", "Notice", "The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled \"Scientific Considerations in Demonstrating Biosimilarity to a Reference Product.\" This draft guidance is intended to assist sponsors in demonstrating that a proposed therapeutic protein product is biosimilar to a reference product for the purpose of submitting a marketing application through an abbreviated licensure pathway. This draft guidance gives an overview of FDA's approach to determining biosimilarity.", "2012-02-15", 2012, 2, "https://www.federalregister.gov/documents/2012/02/15/2012-3552/draft-guidance-for-industry-on-scientific-considerations-in-demonstrating-biosimilarity-to-a", "https://www.govinfo.gov/content/pkg/FR-2012-02-15/pdf/2012-3552.pdf", "Health and Human Services Department; Food and Drug Administration", "221,199", "The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled \"Scientific Considerations in Demonstrating Biosimilarity to a Reference Product.\" This draft guidance is intended to assist sponsors in...", null]], "columns": ["document_number", "title", "type", "abstract", "publication_date", "pub_year", "pub_month", "html_url", "pdf_url", "agency_names", "agency_ids", "excerpts", "regulation_id_numbers"], "primary_keys": ["document_number"], "primary_key_values": ["2012-3552"], "units": {}, "query_ms": 0.41220197454094887, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}